Latest NanOlogy News
-
AUA2021 Presentation Highlights Results from a Phase 1/2 Clinical Trial of Intramural/Intravesical NanoDoce® Suspension in High-Risk Nonmuscle Invasive Bladder CancerSeptember 21, 2021 -
Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 intro 4T1-Luc orthotropic implants reduces primary tumor and metastatic pulmonary lesionsAugust 25, 2021 -
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the PancreasJune 9, 2021 -
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical TrialApril 26, 2021 -
NanOlogy Completes Enrollment of Bladder Cancer Clinical TrialMarch 9, 2021 -
Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studiesNovember 10, 2020 -
NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate CancerNovember 4, 2020 -
Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgerySeptember 17, 2020
